[Transitional cell carcinoma involvement of the prostate]

Area of Science:

• Uro-oncology
• Prostate cancer research
• Bladder cancer management

Context:

• Transitional cell carcinoma of the prostate (PTCC) is an increasingly recognized entity.
• PTCC is part of a broader pan-urothelial disease spectrum.
• Most PTCC cases are secondary, diagnosed concurrently with bladder cancer.

Purpose:

• To highlight the diagnostic and management considerations for PTCC.
• To differentiate between primary and secondary PTCC.
• To discuss the prognostic implications and treatment strategies for PTCC based on invasion depth.

Summary:

• PTCC incidence is rising due to increased awareness and detection.
• Primary PTCC is rare, while secondary PTCC often presents with bladder cancer.
• Prognosis and treatment depend on the degree of prostate invasion; non-invasive PTCC may be managed conservatively, whereas invasive PTCC requires aggressive treatment like radical cystectomy.

Impact:

• Emphasizes the importance of considering the prostate in urothelial cancer management.
• Underscores the need for a reliable staging system for PTCC.
• Informs surgical decisions regarding urinary diversion in patients with PTCC undergoing radical cystectomy.